Bangalore-based start-up, Cardiotrack, a fast growing predictive diagnostic technology platform

22nd February, 2017 Bangalore: Bangalore-based start-up, Cardiotrack, which provides best-in-class predictive diagnosis for cardiovascular diseases, is strengthening its footprint in Mexico, France, and India as well. Cardiotrack, is a global name that uses innovative medical technology to create breakthrough diagnostic products in the cardiac space and improve people’s lives.

Cardiotrack, on Tuesday, announced that it inked a Memorandum of Understanding (MoU) with Grupo Seara, one of the largest entrepreneurial healthcare services companies in Mexico. Founded by Eduardo Serna Barragan, Grupo Seara will adopt advanced patient-centric technologies from Cardiotrack to deliver high-level operational efficiency and quality diagnostics for the patients at an affordable cost.

Founded by industry veterans Ashim Roy and Avin Agrawal, the Cardiotrack platform is designed to fulfill the basic requirements of primary care. Using Cardiotrack, doctors can detect heart health problems accurately, consult specialists, refer and track patients, maintain medical history and start the intervention process.  At a time when coronary heart disease is one of the major healthcare challenges facing the World, Cardiotrack is addressing the concern through its innovative diagnostic solutions for cardiac care, globally.

The MoU was signed at the TEPC event, 2017 in the presence of the senior leadership teams from both companies. A similar MoU was signed with Cardiologs, a French AI company, to deliver best-in-class predictive diagnosis for cardiovascular diseases. In fact, Cardiotrack, recognized globally for its robust hardware, will be integrated with AI software developed and deployed in France.

Cardiotrack’s collaborations will revolutionize theway cardiovascular diseases are diagnosed. The solutions will offer featuresthat are currently only available in ECG machines priced many times higher. TheAI based solution is designed for use in primary healthcare clinics (PHC) andwill bring a tremendous change to affordability and accessibility of quality hearthealth diagnosis and intervention.

Talking about the collaborations, Ashim Roy,co-founder, Cardiotrack, said, “It gives us greatpleasure to collaborate with internationally reputed companies. It is atestimony of our commitment to make healthcare delivery more efficient,effective and affordable through innovative healthcare products. SinceCardiotrack’s inception in September 2015, approximately over 16,000patient scans havebeen done using over 200 devices. The deployments have been in India as well asin countries such as Myanmar, Indonesia, Mexico and U.S.A.”

“The healthcare industry has made massive strides inthe past few years with digital health technologies. However, new age medicaldiagnostics tools provided by global leaders that are designed for the needs oflarge hospitals and clinics, are often too expensive and require significantamount of training. That makes them unsuitable for primary care physicians. Infact, the problem becomes acute in semi-urban areas of the Asian sub-continent,where the lack of diagnostic capabilities at primary care centers results in alack of proper healthcare delivery. Cardiotrack, a disruptive diagnosticplatform, is based on years of extensive research and data mining thataddresses these challenges and simplifies the process,” saidAvinAgrawal, co-founder, Cardiotrack.

Cardiotrack’s parent company uber Diagnostics isheadquartered in Singapore. The focus is to usher in a technology revolution inthe healthcare sector through its diagnostic and intervention platform. Thecompany employs highly evolved technology in medical electronics, dataanalytics, cloud storage and diagnostics workflow management. 

Cardiotrack platform includes multi-parameter, lightweight healthcare IoT devices and mobile health software that helps screenillnesses such as cardiovascular diseases and hypertension, and helps doctorsperform diagnosis and then safely store the patient records.

  (0)   Comment